



**LONG ALDRIDGE
& NORMAN^{LLP}**
ATTORNEYS AT LAW

701 PENNSYLVANIA AVENUE, N.W. • SUITE 600
WASHINGTON, D.C. 20004
202 624-1200 • FACSIMILE 202 624-1298

ATLANTA, GA OFFICE
303 PEACHTREE STREET • SUITE 5300
ATLANTA, GA 30308
404 527-4000 • FACSIMILE 404 527-4198

1652
RECEIVED

SEP 20 1990

TECH CENTER 1600/2900

| | |
|--|----------------|
| CERTIFICATE OF MAILING | |
| 37 C.F.R. §1.8 | |
| I hereby certify that this paper is being deposited with the U.S. Postal Service as First-Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date shown below: | |
| Date | Susan F. Mahon |

DOCKET NO.: 9561-018-27 DIV

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Re: Serial No.: 09/007,306
Applicant(s): JENNIFER L. HILLMAN
Filing Date: JANUARY 15, 1998
For: A NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE
Group Art Unit: 1652
Examiner: NASHED, N.

RECEIVED
1999 OCT 21 PM 2:43
BOARD OF PATENT APPEALS
AND INTERFERENCE

SIR:

Attached hereto for filing are the following papers:

CERTIFICATE UNDER 37 C.F.R. §3.73(b),
AND APPOINTMENT OF NEW ATTORNEYS

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 50-0911. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. §1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

LONG ALDRIDGE & NORMAN LLP

Steven B. Kelber

Attorney of Record

Registration No.: 30,073

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on _____
By: _____ Printed: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jennifer L. Hillman

Title: A NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE

Serial No.: 09/007,306

Filing Date: January 15, 1998

Examiner: N. Nashed

Group Art Unit: 1652

Batch No. G26



Assistant Commissioner for Patents
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
AND APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above identified patent application and, to the best of undersigned's knowledge and belief, title in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3174 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8554, Frame 0748, hereby appoints the following patent attorneys/agents whose post office address is Long, Aldridge & Norman, LLP, 701 Pennsylvania Avenue, NW, Suite 600, Washington, D.C. 20004:

Steven B. Kelber

Reg. No. 30,073

Sharon E. Crane, Ph.D.

Reg. No. 36,113

Please direct all correspondence to:

RECEIVED
1999 OCT 21 PM 2:45
BOARD OF PATENT APPEALS
AND INTERFERENCES

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Lucy J. Billings,
Incyte Pharmaceuticals, Inc., Phone: (650) 855-0555, Fax: (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: 9/3/99

By: Lee Bendekgey
Lee Bendekgey
VP Legal Affairs/Corporate Secretary